Overview

* Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement

* Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year

* Palatin ( PTN ) completes $18.2 mln public offering, regains NYSE American compliance

Outlook

* Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026

* Palatin ( PTN ) expects mid-2026 IND filing for next-gen MC4R agonists

* Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity

Result Drivers

* BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement

* PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 EPS $4.26

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)